Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting

NEXT STORY
OpGen Announces Results from Successful Webinar on Bacterial Pneumonia Co-infections in COVID-19 Patients
PREV STORY
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

-- Late-breaking oral presentations to highlight data from plazomicin Phase 3 EPIC and CARE ...

author_avatar
NASDAQ Market News

Oncology Pharma, Inc. Narrows Focus on Funding Efforts

author_avatar
NASDAQ Market News

Merus annonce la publication d’un résumé sur le zenocutuzumab dans les cancers à fusion du gène NRG1 (NRG1+) lors de l’assemblée annuelle 2021 de l’American Society of Clinical Oncology (ASCO)

author_avatar
NASDAQ Market News